2. Anti-infection
  3. Influenza Virus
  4. KIN1148

KIN1148, a small-molecule IRF3 agonist, is a novel influenza vaccine adjuvant found to enhance flu vaccine efficacy.

For research use only. We do not sell to patients.

KIN1148 Chemical Structure

KIN1148 Chemical Structure

CAS No. : 1428729-56-9

Size Price Stock Quantity
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 374 In-stock
Solution
10 mM * 1 mL in DMSO USD 374 In-stock
Solid
1 mg USD 180 In-stock
5 mg USD 340 In-stock
10 mg USD 490 In-stock
25 mg USD 790 In-stock
50 mg USD 1050 In-stock
100 mg USD 1400 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

KIN1148 Related Antibodies

Top Publications Citing Use of Products

    KIN1148 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2023 Mar 31;118:110104.  [Abstract]

    KIN1148 (10 μM) significantly increases the expressions of NLRP3, GSDMD-NT, and CASP-1 p20 while partially abolishes the inhibitory effect of 4-OI (4-octyl itaconate) on MH-S cells.

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    KIN1148, a small-molecule IRF3 agonist, is a novel influenza vaccine adjuvant found to enhance flu vaccine efficacy.

    In Vitro

    KIN1148 induces the dose-dependent nuclear translocation of IRF3 in PH5CH8 cells and specific activation of IRF3- responsive promoters. KIN1148 also elicits greater induction of endogenous IRF3-dependent ISG54 and OASL expression by PH5CH8 cells[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    KIN1148 Related Antibodies
    In Vivo

    Prime-boost immunization of mice with a suboptimal dose of a monovalent pandemic influenza split virus H1N1 A/California/07/2009 vaccine plus KIN1148 protect against a lethal challenge with mouse-adapted influenza virus (A/California/04/2009) and induce an influenza virusspecific IL-10 and Th2 response by T cells derived from lung and lung-draining lymph nodes. Primeboost immunization with vaccine plus KIN1148, but not prime immunization alone, induce antibodies capable of inhibiting influenza virus hemagglutinin and neutralizing viral infectivity. Nevertheless, a single immunization with vaccine plus KIN1148 provide increased protection over vaccine alone and reduce viral load in the lungs after challenge[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Molecular Weight

    361.44

    Formula

    C19H11N3OS2
    CAS No.
    Appearance

    Solid

    Color

    Light yellow to yellow

    SMILES

    O=C(NC1=NC2=CC=C3C(N=CS3)=C2S1)C4=CC5=C(C=C4)C=CC=C5
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 100 mg/mL (276.67 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.7667 mL 13.8336 mL 27.6671 mL
    5 mM 0.5533 mL 2.7667 mL 5.5334 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    Purity & Documentation
    References
    Animal Administration
    [1]

    Mice: The final liposomes prior to mixing with vaccine contained KIN1148 (5 mg/mL) and phospholipids (40 mg/mL) and are delivered intramuscularly (KIN1148 at 50 μg and phospholipid at 400 μg per dose). Blank liposomes are prepared without KIN1148 as vehicle control. KIN1148 liposome and blank liposome formulations are stable for at least 4 months at 4°C and are used for in vivo experiments within a month after preparation[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.7667 mL 13.8336 mL 27.6671 mL 69.1678 mL
    5 mM 0.5533 mL 2.7667 mL 5.5334 mL 13.8336 mL
    10 mM 0.2767 mL 1.3834 mL 2.7667 mL 6.9168 mL
    15 mM 0.1844 mL 0.9222 mL 1.8445 mL 4.6112 mL
    20 mM 0.1383 mL 0.6917 mL 1.3834 mL 3.4584 mL
    25 mM 0.1107 mL 0.5533 mL 1.1067 mL 2.7667 mL
    30 mM 0.0922 mL 0.4611 mL 0.9222 mL 2.3056 mL
    40 mM 0.0692 mL 0.3458 mL 0.6917 mL 1.7292 mL
    50 mM 0.0553 mL 0.2767 mL 0.5533 mL 1.3834 mL
    60 mM 0.0461 mL 0.2306 mL 0.4611 mL 1.1528 mL
    80 mM 0.0346 mL 0.1729 mL 0.3458 mL 0.8646 mL
    100 mM 0.0277 mL 0.1383 mL 0.2767 mL 0.6917 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    KIN1148 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    KIN11481428729-56-9KIN 1148KIN-1148Influenza VirusInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    KIN1148
    Cat. No.:
    HY-101950
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.